Home > Oncology > Abiraterone therapy tied to longer survival in Black vs. white men with metastatic castration-resistant prostate cancer

Abiraterone therapy tied to longer survival in Black vs. white men with metastatic castration-resistant prostate cancer


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Journal
JAMA Network Open
Reuters Health - 13/01/2022 - African American men with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone survive longer than their non-Hispanic white counterparts, a new study suggests. "Our study demonstrated that abiraterone for first-line mCRPC therapy was associated with better outcomes for African American men compared to non-Hispanic White men in a real-world predominantly community-based practice setting," said lead author Dr. Mallika Marar of Stanford University in California. "This difference in outcomes may be driven by decreased benefit of abiraterone, relative to other therapies like enzalutamide, among non-Hispanic White men," she told Reuters Health by email. As reported in JAMA Network Open, Dr. Marar and her colleagues used a nationwide database of 3,808 men receiving first-line therapy for mCRPC over a seven-year period at roughly 280 cancer clinics in the U.S. The patients were newly diagnosed with mCRPC and w...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on